These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 22459734)

  • 41. A multi-analyte panel for non-invasive pharmacokinetic monitoring of second-line anti-tuberculosis drugs.
    Gerona R; Wen A; Koss C; Bacchetti P; Gandhi M; Metcalfe J
    Int J Tuberc Lung Dis; 2016 Jul; 20(7):991-2. PubMed ID: 27287660
    [No Abstract]   [Full Text] [Related]  

  • 42. The clinical management of drug-resistant tuberculosis.
    Furin J
    Curr Opin Pulm Med; 2007 May; 13(3):212-7. PubMed ID: 17414129
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Attributable factors to the emergence of multidrug-resistant Mycobacterium tuberculosis based on the observation of consecutive drug resistance test results].
    Fujino T; Hasegawa N; Satou R; Komatsu H; Kawada K
    Kekkaku; 1998 Jul; 73(7):471-6. PubMed ID: 9739579
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis.
    Worley MV; Estrada SJ
    Pharmacotherapy; 2014 Nov; 34(11):1187-97. PubMed ID: 25203970
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Multidrug-resistant tuberculosis: resistance rates to first and reserve antituberculosis drugs in the UK in 2008/9 and the role of rapid molecular tests for drug resistance.
    Mitchell SL; Seoudi N; Hutchison DC; Drobniewski FA
    Thorax; 2011 Jul; 66(7):630-1. PubMed ID: 20880876
    [No Abstract]   [Full Text] [Related]  

  • 46. Integrating drug concentrations and minimum inhibitory concentrations with Bayesian-dose optimisation for multidrug-resistant tuberculosis.
    Srivastava S; Gumbo T
    Eur Respir J; 2014 Jan; 43(1):312-3. PubMed ID: 24381327
    [No Abstract]   [Full Text] [Related]  

  • 47. Drug-resistant Mycobacterium tuberculosis, Taiwan.
    Jou R; Chuang PC; Wu YS; Yan JJ; Luh KT
    Emerg Infect Dis; 2006 May; 12(5):871-2. PubMed ID: 16710962
    [No Abstract]   [Full Text] [Related]  

  • 48. Fluoroquinolones resistance in multidrug-resistant tuberculosis in Pakistan and suitability of guidelines recommended standardized regimen.
    Ahmad N; Khan AH; Syed Sulaiman SA; Javaid A
    Int J Mycobacteriol; 2015 Sep; 4(3):258-9. PubMed ID: 27649876
    [No Abstract]   [Full Text] [Related]  

  • 49. DOTS and drug resistance: a silver lining to a darkening cloud.
    Chaisson RE; Coberly JS; De Cock KM
    Int J Tuberc Lung Dis; 1999 Jan; 3(1):1-3. PubMed ID: 10094162
    [No Abstract]   [Full Text] [Related]  

  • 50. The shorter multidrug-resistant tuberculosis treatment regimen in Singapore: are patients from South-East Asia eligible?
    Chee CBE; KhinMar KW; Sng LH; Jureen R; Cutter J; Lee VJM; Wang YT
    Eur Respir J; 2017 Aug; 50(2):. PubMed ID: 28798092
    [No Abstract]   [Full Text] [Related]  

  • 51. Fluoroquinolones in multidrug-resistant tuberculosis.
    Mohapatra PR
    Am J Respir Crit Care Med; 2004 Oct; 170(8):920-1. PubMed ID: 15475406
    [No Abstract]   [Full Text] [Related]  

  • 52. Wild-type distributions of seven oral second-line drugs against Mycobacterium tuberculosis.
    Schön T; Juréen P; Chryssanthou E; Giske CG; Sturegård E; Kahlmeter G; Hoffner S; Angeby KA
    Int J Tuberc Lung Dis; 2011 Apr; 15(4):502-9. PubMed ID: 21396210
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Shortened, strictly supervised tuberculosis treatment in populations with moderate drug resistance levels: international impact perspective].
    Santos-Preciado JI; Franco-Paredes C
    Rev Invest Clin; 2005; 57(3):488-90. PubMed ID: 16187710
    [No Abstract]   [Full Text] [Related]  

  • 54. Emerging resistant clone of Mycobacterium tuberculosis in west Asia.
    Mokrousov I
    Lancet Infect Dis; 2016 Dec; 16(12):1326-1327. PubMed ID: 27998587
    [No Abstract]   [Full Text] [Related]  

  • 55. Mycobacterium tuberculosis "Beijing" epidemics: a race against mutations?
    Bhatter P; Chatterjee A; Mistry N
    Tuberculosis (Edinb); 2012 Jan; 92(1):92-4. PubMed ID: 22015174
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Molecular mechanisms of the formation of drug resistance of Mycobacterium tuberculosis (review of the literature)].
    Tungusova OS; Mar'iandyshev AO
    Probl Tuberk; 2001; (6):48-9. PubMed ID: 11641963
    [No Abstract]   [Full Text] [Related]  

  • 57. Bedaquiline.
    Goulooze SC; Cohen AF; Rissmann R
    Br J Clin Pharmacol; 2015 Aug; 80(2):182-4. PubMed ID: 25702772
    [No Abstract]   [Full Text] [Related]  

  • 58. Treatment of tuberculosis with levofloxacin or moxifloxacin: report of 6 pediatric cases.
    Chauny JV; Lorrot M; Prot-Labarthe S; De Lauzanne A; Doit C; Géréral T; Bourdon O
    Pediatr Infect Dis J; 2012 Dec; 31(12):1309-11. PubMed ID: 22814964
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rapid emergence of
    Veziris N; Bernard C; Guglielmetti L; Le Du D; Marigot-Outtandy D; Jaspard M; Caumes E; Lerat I; Rioux C; Yazdanpanah Y; Tiotiu A; Lemaitre N; Brossier F; Jarlier V; Robert J; Sougakoff W; Aubry A; ;
    Eur Respir J; 2017 Mar; 49(3):. PubMed ID: 28182568
    [No Abstract]   [Full Text] [Related]  

  • 60. New generation methods for drug susceptibility testing for tuberculosis.
    Katoch VM
    Indian J Tuberc; 2008 Apr; 55(2):61-3. PubMed ID: 18516820
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.